Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relamorelin for Diabetic Gastroparesis – 12-week Phase 3 RCT
2017-002177-20Phase 3Terminated
- Sponsor
- Allergan
- Start
- Jun 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic gastroparesis comparing Relamorelin with Placebo (2 arms). Primary endpoint: Change from baseline to Week 12 in weekly Diabetic Gastroparesis Symptom Severity Score (DGSSS). Started Jun 2018; status: terminated.
02
Drugs
relamorelin
03
Conditions
diabetic gastroparesis
Beyond the preview
Go deeper on 2017-002177-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002177-20.